Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brinzolamide

FDA-approved product (suspension/drops, ophthalmic), marketed as Azopt, Brinzolamide.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brinzolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
FDA pharmacologic class
Carbonic Anhydrase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis83.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Brinzolamide in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brinzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

    NCT07074782 · start 2026-05

    Registered record
    Registry ID
    NCT07074782
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2026-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

    NCT06883123 · start 2025-05-14

    Registered record
    Registry ID
    NCT06883123
    Conditions
    Open Angle Glaucoma
    Interventions
    Simbrinza 0.2%-1% Ophthalmic Suspension; Rocklatan 0.02%-0.005% Ophthalmic Solution; Cosopt PF 2%-0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-14
    Completion
    2026-04-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma
    InterventionSimbrinza 0.2%-1% Ophthalmic Suspension; Rocklatan 0.02%-0.005% Ophthalmic Solution; Cosopt PF 2%-0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution
    PhasePhase 4
    Registry statusRecruiting

  • A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

    NCT05022004 · start 2021-12-20

    Registered record
    Registry ID
    NCT05022004
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide ophthalmic suspension; Azopt®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-12-20
    Completion
    2023-01-06
    Enrolment
    599

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide ophthalmic suspension; Azopt®
    PhasePhase 3
    Registry statusCompleted

  • To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

    NCT04944290 · start 2021-05-28

    Registered record
    Registry ID
    NCT04944290
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Brinzolamide/brimonidine ophthalmic suspension; Simbrinza 0.2%/1% Ophthalmic Suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-28
    Completion
    2022-06-21
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionBrinzolamide/brimonidine ophthalmic suspension; Simbrinza 0.2%/1% Ophthalmic Suspension
    PhasePhase 3
    Registry statusCompleted

  • Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

    NCT04676126 · start 2021-05

    Registered record
    Registry ID
    NCT04676126
    Conditions
    Glaucoma; Glaucoma Eye; Glaucoma, Open-Angle
    Interventions
    Lumega-Z; Dorzolamide Hcl 2% Oph Soln; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-05
    Completion
    2022-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Glaucoma Eye; Glaucoma, Open-Angle
    InterventionLumega-Z; Dorzolamide Hcl 2% Oph Soln; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

    NCT04024072 · start 2019-06-24

    Registered record
    Registry ID
    NCT04024072
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Brinzolamide 1% ophthalmic suspension; Azopt 1% Ophthalmic Suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-24
    Completion
    2020-04-30
    Enrolment
    495

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionBrinzolamide 1% ophthalmic suspension; Azopt 1% Ophthalmic Suspension
    PhasePhase 3
    Registry statusCompleted

  • Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

    NCT03542006 · start 2018-06-01

    Registered record
    Registry ID
    NCT03542006
    Conditions
    Central Serous Chorioretinopathy
    Interventions
    Brinzolamide Ophthalmic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-06-01
    Completion
    2019-04-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Serous Chorioretinopathy
    InterventionBrinzolamide Ophthalmic
    PhasePhase 2
    Registry statusUnknown

  • Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

    NCT03896633 · start 2018-02-28

    Registered record
    Registry ID
    NCT03896633
    Conditions
    Glaucoma; Open Angle or Ocular Hypertension
    Interventions
    brinzolamide 1% ophthalmic suspension; Azopt 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-02-28
    Completion
    2018-11-17
    Enrolment
    637

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Open Angle or Ocular Hypertension
    Interventionbrinzolamide 1% ophthalmic suspension; Azopt 1%
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

    NCT03150160 · start 2017-09-21

    Registered record
    Registry ID
    NCT03150160
    Conditions
    Glaucoma
    Interventions
    brinzolamide 1%/brimonidine 0.2% fixed combination; Placebo; travoprost 0.004% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-21
    Completion
    2017-12-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Interventionbrinzolamide 1%/brimonidine 0.2% fixed combination; Placebo; travoprost 0.004% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification

    NCT03494257 · start 2017-09-04

    Registered record
    Registry ID
    NCT03494257
    Conditions
    Cataract; Intraocular Pressure
    Interventions
    Brinzolamide-Brimonidine fixed combination
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-09-04
    Completion
    2018-04-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract; Intraocular Pressure
    InterventionBrinzolamide-Brimonidine fixed combination
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

    NCT02730871 · start 2016-06-24

    Registered record
    Registry ID
    NCT02730871
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide/brimonidine vehicle; Travoprost 0.004%/timolol 0.5% solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-06-24
    Completion
    2018-07-13
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide/brimonidine vehicle; Travoprost 0.004%/timolol 0.5% solution
    PhasePhase 4
    Registry statusTerminated

  • Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

    NCT03192826 · start 2016-06-20

    Registered record
    Registry ID
    NCT03192826
    Conditions
    Posterior Capsule Opacification; Ocular Hypertension
    Interventions
    Brinzolamide/Brimonidine FC; Brimonidine 0.2%; Artificial tears
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06-20
    Completion
    2017-07-08
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosterior Capsule Opacification; Ocular Hypertension
    InterventionBrinzolamide/Brimonidine FC; Brimonidine 0.2%; Artificial tears
    PhasePhase 4
    Registry statusCompleted

  • 24-hr Intraocular Pressure Control With SIMBRINZA ®

    NCT02770248 · start 2016-05-23

    Registered record
    Registry ID
    NCT02770248
    Conditions
    Glaucoma
    Interventions
    Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05-23
    Completion
    2017-01-14
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionBrinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Vehicle
    PhasePhase 4
    Registry statusCompleted

  • Stop Retinal Ganglion Cell Dysfunction Study

    NCT02390284 · start 2015-09

    Registered record
    Registry ID
    NCT02390284
    Conditions
    Glaucoma
    Interventions
    Latanoprost; Bimatoprost; Travoprost; Timolol; Dorzolamide; Brinzolamide; Acetazolamide; Methazolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2024-10-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionLatanoprost; Bimatoprost; Travoprost; Timolol +4 more
    PhasePhase 3
    Registry statusTerminated

  • SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

    NCT02419508 · start 2015-08-07

    Registered record
    Registry ID
    NCT02419508
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Brinz/brim vehicle; Prostaglandin analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08-07
    Completion
    2018-02-27
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Brinz/brim vehicle; Prostaglandin analogue
    PhasePhase 4
    Registry statusCompleted